Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD37 in acute myeloid leukemia: a novel surface target for drug delivery.
Jeremy E, Artiga E, Elgamal S, Cheney C, Eicher D, Zalponik K, Orwick S, Mao C, Wasmuth R, Harrington B, Mustonen A, Beshay P, Halley P, Castro C, Williams K, Hing Z, Chen T, Lucas C, Vantangoli NJ, Lapalombella R, Grieselhuber N, Mo X, Hertlein E, Muthusamy N, Mundy-Bosse BL, Byrd JC, Larkin KT. Jeremy E, et al. Among authors: wasmuth r. Blood Adv. 2025 Jan 14;9(1):1-14. doi: 10.1182/bloodadvances.2024013590. Blood Adv. 2025. PMID: 39348689 Free PMC article.
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC. McWilliams EM, et al. Among authors: wasmuth r. Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684. Blood Adv. 2019. PMID: 30737226 Free PMC article.
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA, Mehmood A, Jeon JY, Carmichael B, Lehman A, Orwick SJ, Truxall J, Goettl VM, Wasmuth R, Tran M, Mitchell S, Lapalombella R, Eathiraj S, Schwartz B, Stegmaier K, Baker SD, Hertlein E, Byrd JC. Elgamal OA, et al. Among authors: wasmuth r. J Hematol Oncol. 2020 Jan 28;13(1):8. doi: 10.1186/s13045-019-0821-7. J Hematol Oncol. 2020. PMID: 31992353 Free PMC article.
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, Wasmuth R, Beaver L, Cempre C, Skinner J, Cannon M, Govande M, Harrington B, Lehman A, Byrd JC, Lapalombella R, Blachly JS. Brinton LT, et al. Among authors: wasmuth r. J Hematol Oncol. 2020 Oct 19;13(1):139. doi: 10.1186/s13045-020-00973-4. J Hematol Oncol. 2020. PMID: 33076970 Free PMC article.
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N. Mani R, et al. Among authors: wasmuth r. Haematologica. 2018 Aug;103(8):1288-1297. doi: 10.3324/haematol.2018.188193. Epub 2018 May 17. Haematologica. 2018. PMID: 29773600 Free PMC article.
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
Lucas F, Rogers KA, Harrington BK, Pan A, Yu L, Breitbach J, Bundschuh R, Goettl VM, Hing ZA, Kanga P, Mantel R, Sampath D, Smith LL, Wasmuth R, White DK, Yan P, Byrd JC, Lapalombella R, Woyach JA. Lucas F, et al. Among authors: wasmuth r. Clin Cancer Res. 2019 Oct 15;25(20):6260-6273. doi: 10.1158/1078-0432.CCR-19-0273. Epub 2019 Jul 11. Clin Cancer Res. 2019. PMID: 31296529 Free PMC article.
13 results